Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Carcinoma × donafenib × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 18 Liver Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma 2 Recurrence 1 Pancreatic Neoplasms 1 Esophageal Neoplasms 1 Digestive System Neoplasms 1 Cirrhosis, Familial, with Pulmonary Hypertension 1 Biliary Tract Carcinoma 1 Biliary Tract Adenocarcinoma 1 Biliary Malignant Tumors 1

Interventions

Oxaliplatin 2 tislelizumab 1 sintilimab 1 donafenib 1 Immunotherapy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04979663 2021-08-09

GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Fudan University

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡